3,4-Dimethylmethcathinone

3,4-Dimethylmethcathinone
Clinical data
ATC code	none;
Legal status
Legal status	DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name (±)-1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one;
CAS Number	1082110-00-6 ;
PubChem CID	52988261;
ChemSpider	25630192 ;
UNII	C4EW58DTW5;
CompTox Dashboard (EPA)	DTXSID501016968 ;
Chemical and physical data
Formula	C12H17NO
Molar mass	191.274 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(C(=O)C(C)NC)cc1C;
	InChI InChI=1S/C12H17NO/c1-8-5-6-11(7-9(8)2)12(14)10(3)13-4/h5-7,10,13H,1-4H3 ; Key:IBZRXTVDTGVBIS-UHFFFAOYSA-N ;
	(what is this?) (verify)

3,4-Dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone, following its widespread abuse in many countries in Europe and around the world.^[1] 3,4-DMMC has been seized as a designer drug in Australia.^[2] In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake, and to a lesser extent dopamine reuptake.^[3]